# The type of endometrial preparation for embryo transfer after egg donation affects obstetric outcomes and the expression of placental angiogenic biomarkers

**Authors:** Andrea Roberto Carosso, Alessandro Rolfo, Valeria Maria Savasi, Enrico Papaleo, Laura Moretti, Anna Maria Nuzzo, Marco Carosso, Gianvito Contangelo, Ilaria Stura, Maria Elena Iacovazzi, Alberto Revelli, Gianluca Gennarelli

PMC · DOI: 10.1186/s12958-025-01521-w · Reproductive Biology and Endocrinology : RB&E · 2026-01-03

## TL;DR

Using natural or modified natural cycles for embryo transfer in egg donation leads to better pregnancy and baby outcomes compared to artificial cycles.

## Contribution

This study shows that natural/modified natural cycles reduce pregnancy complications and improve placental angiogenic biomarker expression in oocyte donation.

## Key findings

- Natural/modified natural cycles had lower rates of preeclampsia and placental previa compared to artificial cycles.
- Babies born after natural/modified natural cycles had lower rates of low birth weight and ICU admission.
- Natural cycles showed higher pro-angiogenic gene expression, while artificial cycles had increased anti-angiogenic markers.

## Abstract

We investigated the impact of natural cycle/modified natural cycle and artificial cycle in oocyte donation pregnancies on obstetric/neonatal outcomes and placental angiogenic biomarkers.

A total number of 201 singleton live births resulted from in vitro fertilization with oocyte donation were enrolled: n = 70 after natural cycle/modified natural cycle endometrial preparation and n = 131 after artificial cycle endometrial preparation. Moreover, 35 placental biopsies were collected: n = 12 after natural cycle/modified natural cycle endometrial preparation, n = 23 after artificial cycle endometrial preparation. Finally, 24 placentae from women with a spontaneous, healthy singleton pregnancy at term, who showed no signs of maternal, placental or fetal disease were used as control.

We reported a lower incidence of both hypertensive disorders of pregnancy (7.1% Vs 18.3%, p < 0.05), including preeclampsia, and placental previa (0 Vs 6.1%, p < 0.05) in natural/modified natural cycles compared to artificial cycle. Furthermore, better neonatal outcomes, at least in terms of low birth weight (5.7% Vs 20.9%, p < 0.05) and intensive care unit admission (2.9% Vs 15.6%, p < 0.05), were observed. From a molecular point of view, a significant gene over-expression of pro-angiogenic placental growth factor and vascular endothelial growth factor were obtained in natural cycles. Conversely, anti-angiogenic Soluble Fms-Like Tyrosine Kinase- 1 levels were increased in artificial cycle group placentae compared to natural/modified natural cycle and controls.

Natural/modified cycles should be promoted as preferential approach for endometrial preparation in oocyte donation pregnancies, at least when regular (or inducible) ovulatory cycles are present.

## Linked entities

- **Diseases:** preeclampsia (MONDO:0005081)

## Full-text entities

- **Genes:** FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PAPPA (pappalysin 1) [NCBI Gene 5069] {aka ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1}, PTBP1 (polypyrimidine tract binding protein 1) [NCBI Gene 5725] {aka HNRNP-I, HNRNPI, HNRPI, PTB, PTB-1, PTB-T}, PIGF (phosphatidylinositol glycan anchor biosynthesis class F) [NCBI Gene 5281] {aka OORS}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** endometriosis (MESH:D004715), OD (OMIM:615774), premature ovarian failure (MESH:D016649), placental dysfunction (MESH:D010922), Hypertensive disorders (MESH:D006973), anovulation (MESH:D000858), blood loss (MESH:D016063), PE (MESH:D011225), IVF (MESH:C566179), AC (MESH:D000091622), IUGR (MESH:D005317), premature rupture of membranes (MESH:D005322), neonatal macrosomia (MESH:D007232), pPROM (MESH:C563032), PPH (MESH:D050032), preterm birth (MESH:D047928), infertility (MESH:D007246), Gestational diabetes (MESH:D016640), HDP (MESH:D046110), pregnancy loss (MESH:D000022), disease (MESH:D004194), endothelial dysfunction (MESH:D014652), necrotic (MESH:D009336), Pregnancy (MESH:D011254), inflammation (MESH:D007249), CL (MESH:D010048)
- **Chemicals:** heparin (MESH:D006493), AC (-), Estradiol (MESH:D004958), ACs (MESH:D000186), ASA (MESH:D001241), letrozole (MESH:D000077289), progesterone (MESH:D011374), clomiphene (MESH:D002996)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12870173/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12870173/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12870173/full.md

---
Source: https://tomesphere.com/paper/PMC12870173